Skip to content

Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy

BALCoS - Basel Long COVID Cohort Study and DiLCoS - Digital Long COVID Substudy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05781893
Acronym
BALCoS/DiLCoS
Enrollment
196
Registered
2023-03-23
Start date
2023-04-20
Completion date
2026-05-06
Last updated
2026-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post COVID-19 Condition (PCC)

Keywords

Coronavirus disease (COVID), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Somatic Symptom Disorder (SSD), fatigue, shortness of breath, cognitive dysfunction

Brief summary

The Basel Long COVID Cohort Study (BALCoS) is a registry-based cohort study that focuses on the patients' present health status, symptoms, the course of these symptoms, and potential mechanisms involved. The project aims to investigate proposed mechanisms behind Post COVID-19 condition (PCC), including a) autoimmunity, b) chronic inflammation, c) genetics, d) coagulation disorders, and e) psychosocial factors. Patients in the cohort can also join the Digital Long COVID Study (DiLCoS), a single-arm, cohort-based proof-of-feasibility study that is part of the larger BALCoS. DiLCoS is a intervention substudy designed to evaluate whether doing exercises delivered via a smartphone app (referred as digital intervention) can help with PCC. The digital intervention is a 12-week program that includes different kinds of exercises like breathing exercises, relaxation techniques, and tips on managing fatigue and other symptoms. It also teaches patients how to monitor their activities and energy levels, and provides psychological exercises to cope with negative thoughts and pain. Patients in the cohort complete a set of assessments that include the collection of sociodemographic and clinical data, biomarkers, neurocognitive testing, psychometric questionnaires, and measures of physical performance, and provide consent that their data from routine clinical care can be used for the study.

Interventions

OTHERDigital intervention (DiLCoS)

The DiLCoS substudy comprises a digital intervention. A smartphone app is used to provide the patient with a 12-week exercise program, including physical elements (in the form of breathing exercises, relief positions and relaxation techniques), psychoeducational elements (e.g., information about fatigue, neurocognitive symptoms, media consumption, healthy diet), self-monitoring elements (activity planning, energy management), and psychological elements (e.g., guided exercises to improve acceptance of current situation, cognitive distancing from negative thoughts, imagination techniques for pain management). It holds promise for significantly improving the management and quality of life of individuals living with PCC.

OTHERData collection

Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER
State Secretariat for Education Research and Innovation, Switzerland
CollaboratorOTHER
European Union's Horizon Europe research and innovation programme
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with PCC will be included. PCC will be defined as: * History of confirmed or suspected SARS CoV-2 infection * Symptoms usually start within 3 months from the onset of acute SARS CoV-2 infection with symptoms and effects that last for at least 2 months * Symptoms cannot be explained by an alternative diagnosis * signed informed consent is required Additional Inclusion Criteria for participtation in DiLCoS: * A smartphone with a compartible-operating system * Separate signed informed consent is required

Exclusion criteria

* Age \<18 years * Lack of consent to participate in the study * Language barriers (lack of sufficient knowledge of German) * Lack of general understanding of study procedures

Design outcomes

Primary

MeasureTime frameDescription
Change in World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12- item version)At Baseline, T1 (BL + 3 months), T2 (BL + 6 months); T3 (BL + 12 months)The World Health Organization Disability Assessment Schedule (WHODAS 2.0) assesses and classifies disability due to health problems during the past 4 weeks. This study will utilize the 12- item version. Items are answered on a 5-point scale ranging from 0 = "none" to 4 = "extreme or cannot do".

Countries

Switzerland

Contacts

PRINCIPAL_INVESTIGATORGunther Meinlschmidt

University Hospital Basel, Department of Psychosomatic Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026